LinkedIn
WebsiteIntroduction
Predictive Oncology Inc. (NASDAQ: POAI) is a biotechnology company based in Pittsburgh, Pennsylvania, that integrates machine learning with a biobank of tumor samples. The company utilizes its AI-driven platform and three-dimensional tumor models to enhance drug-response predictions, with the objective of advancing molecules into clinical testing.
Corporate Structure
Founded in 2002, Predictive Oncology operates with a workforce of 11–50 employees. Its leadership team and board of directors consist of professionals with backgrounds in genomics, pharmaceutical manufacturing, healthcare IT, and business development. The company maintains a CLIA-certified laboratory and collaborates with academic and commercial partners to support early-stage drug discovery.
Biotechnology by Sangharsh Lohakare
Developments and News
On June 2, 2024, researchers from Predictive Oncology and UPMC Magee-Women’s Hospital presented AI-powered multi-omic models for predicting short- and long-term survival outcomes in ovarian cancer at the American Society of Clinical Oncology Annual Meeting. These models demonstrated improved predictive performance compared to those relying solely on clinical data.
On May 20, 2025, Predictive Oncology issued a shareholder letter outlining the expansion of its AI platform to include biomarker discovery and drug repurposing. The letter referenced a global biomarker discovery market valued at $14.5 billion in 2024, with an expected growth rate of 19.4 percent CAGR through 2030.
In January 2025, the company announced plans to extend the geographic reach of its ChemoFx® live-cell tumor profiling assay into Europe and to increase its availability in the United States. ChemoFx® is designed to measure individual patient tumor responses to chemotherapy in vitro and works alongside the BioSpeciFx® molecular biomarker portfolio.
On September 8, 2025, Predictive Oncology filed a Form D notice of exempt securities offering, indicating capital raises to support ongoing research and development efforts. Subsequent SEC filings include a Form 8-K on September 12, 2025, reporting changes related to Items 5.02 (departure or appointment of directors) and 9.01 (financial statements and exhibits), as well as another Form 8-K on September 25, 2025, covering Items 3.03, 5.03, 5.07, 7.01, and 9.01.
As of September 29, 2025, shares of POAI closed at $1.5897, reflecting a 105.10 percent increase in price with a trading volume of 13,961,404 shares.
Financial and Strategic Analysis
For the twelve months ending June 30, 2025, Predictive Oncology reported revenue of $1.66 million and a net loss of $9.1 million, equating to a loss of $1.13 per diluted share. The balance sheet indicated $506,080 in cash and a levered free cash flow deficit of $5.35 million. Based on a closing share price of $1.5897, the company’s market capitalization was approximately $10.87 million, with an enterprise value of $12.47 million. Price-to-sales and enterprise-value-to-revenue multiples were recorded at 4.19 and 7.49, respectively, and the stock’s five-year beta stood at 1.37.
Strategically, Predictive Oncology leverages its biobank of over 150,000 tumor samples to validate AI drug-response predictions in early stages, addressing clinical trial failure rates. The extension of its platform into biomarker discovery and drug repurposing broadens service offerings, while international expansion of ChemoFx® may enhance service-line revenue growth.
Market Position and Industry Context
Predictive Oncology operates within the precision oncology and drug discovery sector, where AI-driven platforms and patient-derived tumor models are being implemented to reduce late-stage clinical failures. The company's proprietary biobank provides a critical resource for incorporating human tumor heterogeneity at the pre-clinical stage. Collaborations with academic and biopharmaceutical partners strengthen its capabilities as a contract research organization catering to both discovery and translational testing requirements.
The growing demand for biomarker discovery solutions, projected to exceed $14.5 billion in 2024, reflects significant industry interest in early predictive tools. The ability to repurpose previously shelved oncology compounds also offers strategic advantages by creating potentially cost-effective pathways to clinical readiness.
tl;dr
On September 29, 2025, shares of POAI increased by 105.10 percent to $1.5897 on high trading volume. Earlier in September, the company filed a Form D and two Form 8-Ks detailing a securities offering and changes in executive management. In May 2025, Predictive Oncology expanded its AI platform into biomarker discovery and drug repurposing. The January 2025 announcement regarding the launch of ChemoFx® in Europe and the United States aims to broaden commercial services. Future developments may include the implementation of predictive biomarker assays, additional partnerships, and utilizing the biobank to aid drug-development pipelines.
